{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:31:13Z","timestamp":1793316673836,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabres.2025.113056","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:23:59Z","timestamp":1765499039000},"page":"113056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Deinsulinisation in type 2 Diabetes: Evidence-based strategies for safe treatment simplification \u201cApproaches to reducing insulin in type 2 diabetes\u201d"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4709-8696","authenticated-orcid":false,"given":"Carlo B","family":"Giorda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Anelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Goglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano De","family":"Riu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore De","family":"Cosmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Corigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Roberto","family":"Modestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.113056_b0005","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025.Diabetes Care1 January 2025; 48 (Supplement_1): S181\u2013S206.https:\/\/doi.org\/10.2337\/dc25-S009.","DOI":"10.2337\/dc25-S009"},{"issue":"2","key":"10.1016\/j.diabres.2025.113056_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.204","article-title":"Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?","volume":"4","author":"Naing","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.113056_b0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12916-020-01688-6","article-title":"Insulin: too much of a good thing is bad","volume":"18","author":"Kolb","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.diabres.2025.113056_b0020","doi-asserted-by":"crossref","unstructured":"Alexopoulos AS, Soliman D, Lewinski AA, Strawbridge E, Steinhauser K, Edelman D, Crowley M. Simplifying therapy to assure glycemic control and engagement (STAGE) in poorly-controlled diabetes: A pilot study. J Diabetes Complications. 2023 Jan;37(1):108364. doi: 10.1016\/j.jdiacomp.2022.108364. Epub 2022 Dec 5.","DOI":"10.1016\/j.jdiacomp.2022.108364"},{"key":"10.1016\/j.diabres.2025.113056_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108958","article-title":"Simplification of complex insulin therapy: a story of dogma and therapeutic resignation","volume":"178","author":"Giugliano","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.diabres.2025.113056_b0030","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s13300-024-01610-w","article-title":"Expert Opinion on Optimising Type 2 Diabetes Treatment using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification","volume":"15","author":"Haluzik","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.113056_b0035","doi-asserted-by":"crossref","unstructured":"Maiorino MI, Bellastella G, Esposito K, Giugliano D. Premixed insulin regimens in type 2 diabetes: pros Endocrine. 2017 Jan;55(1):45-50. doi: 10.1007\/s12020-016-0917-6. Epub 2016 Mar 22.","DOI":"10.1007\/s12020-016-0917-6"},{"issue":"1","key":"10.1016\/j.diabres.2025.113056_b0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12933-021-01281-y","article-title":"From glucose lowering agents to disease\/diabetes modifying drugs: a \u201cSIMPLE\u201d approach for the treatment of type 2 diabetes","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1 Suppl","key":"10.1016\/j.diabres.2025.113056_b0045","first-page":"1","article-title":"Basal Insulin\/GLP-1 RA Fixed-Ratio Combinations as an option for Advancement of Basal Insulin Therapy in older adults with Type 2 Diabetes","volume":"72","author":"Corriere","year":"2023","journal-title":"J Fam Pract"},{"key":"10.1016\/j.diabres.2025.113056_b0050","doi-asserted-by":"crossref","unstructured":"Hart HE, Ditzel K, Rutten GE, de Groot E, Seidu S, Khunti K, Vos RC. De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study. Patient Prefer Adherence. 2019 Oct 18:13:1775-1783. doi: 10.2147\/PPA.S208947. eCollection 2019.","DOI":"10.2147\/PPA.S208947"},{"key":"10.1016\/j.diabres.2025.113056_b0055","doi-asserted-by":"crossref","unstructured":"Christiaens A, Boureau AS, Guyomarch B, de Decker L, Boland B, Hadjadj S, Cariou B; HYPOAGE Study Group. Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study. Diabetes Care. 2024 Aug 22: dc241058. doi: 10.2337\/dc24-1058. Online ahead of print.","DOI":"10.2337\/figshare.26524384"},{"issue":"12","key":"10.1016\/j.diabres.2025.113056_b0060","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1111\/jgs.18565","article-title":"Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: the Diabetes & Aging Study","volume":"71","author":"Lipska","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2025.113056_b0065","doi-asserted-by":"crossref","unstructured":"Abdelhafiz H, Sinclair AJ. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes J Diabetes Complications. 2018 Apr;32(4):444-450. doi: 10.1016\/j.jdiacomp.2017.11.011. Epub 2017 Nov 29.","DOI":"10.1016\/j.jdiacomp.2017.11.011"},{"issue":"2","key":"10.1016\/j.diabres.2025.113056_b0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.diabres.2008.08.014","article-title":"Can diabetes medication be reduced in elderly patients? an observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control","volume":"82","author":"Sj\u00f6blom","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.diabres.2025.113056_b0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.46747\/cfp.7006391","article-title":"Optimization of type 2 diabetes care in adults aged 65 or older: Practical approach to deintensification","volume":"70","author":"Bardoczi","year":"2024","journal-title":"Can Fam Physician"},{"issue":"1","key":"10.1016\/j.diabres.2025.113056_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001585","article-title":"Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study","volume":"9","author":"Bongaerts","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.113056_b0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jdiacomp.2017.02.014","article-title":"Liberating A1C goals in older adults may not protect against the risk of hypoglycemia","volume":"31","author":"Munshi","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.diabres.2025.113056_b0090","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/jgs.17735","article-title":"Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes","volume":"70","author":"Lederle","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2025.113056_b0095","doi-asserted-by":"crossref","unstructured":"Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes Diabetes Ther. 2021 May;12(5):1227-1247. doi: 10.1007\/s13300-021-01035-9. Epub 2021 Apr.","DOI":"10.1007\/s13300-021-01035-9"},{"key":"10.1016\/j.diabres.2025.113056_b0100","doi-asserted-by":"crossref","unstructured":"Daniela V Pirela, RajeshGarg. De-intensification of diabetes treatment in elderly patients with type 2 diabetes mellitus. EndocrPract. 2019 Dec;25(12):1317-1322. doi: 10.4158\/EP-2019-0303. Epub 2019 Aug 14.","DOI":"10.4158\/EP-2019-0303"},{"key":"10.1016\/j.diabres.2025.113056_b0105","doi-asserted-by":"crossref","unstructured":"Joshua D Niznik, Jacob N Hunnicutt, Xinhua Zhao, Maria K Mor, Florentina Sileanu, Sherrie L Aspinall, Sydney P Springer, Mary J Ersek, Walid F Gellad, Loren J Schleiden, Joseph T Hanlon, Joshua M Thorpe, Carolyn T Thorpe. Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes. J Am GeriatrSoc . 2020 Apr;68(4):736-745. doi: 10.1111\/jgs.16360. Epub 2020 Feb 17.","DOI":"10.1111\/jgs.16360"},{"issue":"4","key":"10.1016\/j.diabres.2025.113056_b0110","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003514","article-title":"Treatment Deintensification is uncommon in adults with Type 2 Diabetes Mellitus: a Retrospective Cohort Study","volume":"10","author":"McAlister","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabres.2025.113056_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108686","article-title":"Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care","volume":"173","author":"Bonora","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2025.113056_b0120","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ulloa AC, Jaime-Casas S, Rosado-Lozoya J, Serrano-P\u00e9rez NH, Hern\u00e1ndez-Ju\u00e1rez D, C\u00e1rdenas-Fragoso Jl, Briones-Garc\u00eda LE, Jim\u00e9nez-Soto R, Garc\u00eda-Padilla C, Garc\u00eda-Lara J, Aguilar-Salinas CA, Hern\u00e1ndez-Jim\u00e9nez S. De-escalating treatment indications for patients who achieve metabolic goals. Diabetes Res Clin Pract. 2024 Feb: 208:111096. doi: 10.1016\/j.diabres.2024.111096. Epub 2024 Jan 18.","DOI":"10.1016\/j.diabres.2024.111096"},{"issue":"9","key":"10.1016\/j.diabres.2025.113056_b0125","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/dc22-2426","article-title":"A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in patients with Poorly Controlled Type 2 Diabetes and very High HbA1c \u22659-15%: DUAL HIGH Trial","volume":"46","author":"Galindo","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.113056_b0130","first-page":"1023","volume":"176","author":"Munshi","year":"2016","journal-title":"Simplification of Insulin Regimen in Older Adults and Risk of Hypoglycemia JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.113056_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00592-022-01974-0","article-title":"De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes","volume":"60","author":"Falcetta","year":"2023","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.diabres.2025.113056_b0140","first-page":"568","article-title":"De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of mean Glycaemia during Fasting Test","volume":"14","author":"Pavlikova","year":"2024","journal-title":"Life (Basel)"},{"issue":"11","key":"10.1016\/j.diabres.2025.113056_b0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.32215","article-title":"Deintensification of Treatment with Sulfonylurea and Insulin after Severe Hypoglycemia among older adults with Diabetes","volume":"4","author":"Alexopoulos","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.113056_b0150","doi-asserted-by":"crossref","unstructured":"Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019 Jan;35(1): e3082. doi: 10.1002\/dmrr.3082. Epub 2018 Oct 18.","DOI":"10.1002\/dmrr.3082"},{"issue":"4","key":"10.1016\/j.diabres.2025.113056_b0155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/dc16-1957","article-title":"Insulin and Glucagon-like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: a Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"40","author":"Maiorino","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113056_b0160","doi-asserted-by":"crossref","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016\/S0140-6736(14)61335-0. Epub 2014 Sep 11.","DOI":"10.1016\/S0140-6736(14)61335-0"},{"issue":"10","key":"10.1016\/j.diabres.2025.113056_b0165","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a Weekly Glucagon-like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: a Randomized Trial","volume":"43","author":"Rosenstock","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2025.113056_b0170","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2337\/dci20-0038","article-title":"Switching from Insulin Bolus Treatment to GLP-1 RAs added to continued Basal Insulin in people with Type 2 Diabetes on Basal-Bolus Insulin","volume":"43","author":"Bolli","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2025.113056_b0175","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s13300-023-01471-9","article-title":"Simplification of complex Insulin Regimens with IdegLira in people with Type 2 Diabetes: Literature Review and Clinical Recommendations","volume":"14","author":"Builes-Monta\u00f1o","year":"2023","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.diabres.2025.113056_b0180","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of Simplification from a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized","volume":"44","author":"Giugliano","year":"2021","journal-title":"Pragmatic Trial Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113056_b0185","doi-asserted-by":"crossref","unstructured":"Champion M, Avila GW, Garcia AE, \u00c1lvarez Delgado FM, Valdez CA. Impact of Initiating a GLP1 Agonist and\/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team. J Prim Care Community Health. 2024 Jan-Dec: 15:21501319241231398. doi: 10.1177\/21501319241231398.","DOI":"10.1177\/21501319241231398"},{"key":"10.1016\/j.diabres.2025.113056_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112341","article-title":"Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life","volume":"144","author":"Rizza","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabres.2025.113056_b0195","doi-asserted-by":"crossref","unstructured":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis, Paschalis et al. Metabolism - Clinical and Experimental, Volume 164, 156113.","DOI":"10.1016\/j.metabol.2024.156113"},{"issue":"4","key":"10.1016\/j.diabres.2025.113056_b0200","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.16174","article-title":"Real-world retrospective study in elderly patients aged 65\u2009years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly)","volume":"27","author":"Fiore","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113056_b0205","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jgs.16372","article-title":"Sarcopenia Definition: the Position statements of the Sarcopenia Definition and Outcomes Consortium","volume":"68","author":"Bhasin","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2025.113056_b0210","doi-asserted-by":"crossref","unstructured":"Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist Leinhard O. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1513-1526. doi: 10.1002\/jcsm.12834. Epub 2021 Oct 29. PMID: 34713982; PMCID: PMC8718078.","DOI":"10.1002\/jcsm.12834"},{"key":"10.1016\/j.diabres.2025.113056_b0215","doi-asserted-by":"crossref","unstructured":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial Sattar, Naveed et al.The Lancet Diabetes & Endocrinology, Volume 13, Issue 6, 482 -493.","DOI":"10.1016\/S2213-8587(25)00027-0"},{"issue":"16","key":"10.1016\/j.diabres.2025.113056_b0220","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.diabres.2025.113056_b0225","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12020-023-03547-9","article-title":"BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes","volume":"83","author":"Giugliano","year":"2024","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.diabres.2025.113056_b0230","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s13300-024-01564-z","article-title":"Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: a 4-Year Follow-up Real-World Study","volume":"15","author":"Di Loreto","year":"2024","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.diabres.2025.113056_b0235","first-page":"1746","article-title":"REX study group. IDegLira for the real world treatment of type 2 diabetes in Italy. final results from the REX observational study","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes ObesMetab"},{"issue":"5","key":"10.1016\/j.diabres.2025.113056_b0240","first-page":"1009","article-title":"Diabetes Care. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in patients with Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: the DUAL VII Randomized Clinical","volume":"41","author":"Billings","year":"2018","journal-title":"Trial"},{"issue":"1","key":"10.1016\/j.diabres.2025.113056_b0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13300-019-00735-7","article-title":"Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in patients with Type 2 Diabetes: Propensity score Matched Analysis","volume":"11","author":"Tab\u00e1k","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.113056_b0250","doi-asserted-by":"crossref","unstructured":"Aika Miya, Akinobu Nakamura, Hideaki Miyoshi, Kyu Yong Cho, So Nagai, Yoshio Kurihara, Shin Aoki, Masataka Taguri, Yasuo Terauchi, Tatsuya Atsumi. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial J Diabetes Investig. 2018 Jan;9(1):119-126. doi: 10.1111\/jdi.12654. Epub 2017 Jul 10.","DOI":"10.1111\/jdi.12654"},{"key":"10.1016\/j.diabres.2025.113056_b0255","doi-asserted-by":"crossref","unstructured":"Pantalone KM, Heller C, Lajara R, Lew E, Li X, Dex T, Kilpatrick CR. Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study. Diabetes Spectr. 2023 Summer;36(3):253-263. doi: 10.2337\/ds22-0064. Epub 2023 Mar 7.","DOI":"10.2337\/ds22-0064"},{"issue":"10","key":"10.1016\/j.diabres.2025.113056_b0260","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/jdi.13533","article-title":"Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: a 24-week randomized controlled trial","volume":"12","author":"Ando","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"17","key":"10.1016\/j.diabres.2025.113056_b0265","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs Insulin Lispro added to Basal Insulin in Type 2 Diabetes: the SURPASS-6 Randomized Clinical Trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2025.113056_b0270","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s13300-019-0673-8","article-title":"Simplifying complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes","volume":"10","author":"Taybani","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.113056_b0275","doi-asserted-by":"crossref","unstructured":"Zolt\u00e1n J Taybani, Bal\u00e1zs B\u00f3tyik, Andr\u00e1s Gyimesi, M\u00f3nika Katk\u00f3, Tam\u00e1s V\u00e1rkonyi. One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes Endocrinol Diabetes Metab. 2023 Jan;6(1):e390. doi: 10.1002\/edm2.390. Epub 2022 Dec 3.","DOI":"10.1002\/edm2.390"},{"issue":"9","key":"10.1016\/j.diabres.2025.113056_b0280","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s13300-023-01435-z","article-title":"Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in patients with Type 2 Diabetes Mellitus: results from the Simplify Study after 6 months","volume":"14","author":"Martinka","year":"2023","journal-title":"Diabetes Ther"},{"issue":"4","key":"10.1016\/j.diabres.2025.113056_b0285","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.amjmed.2008.12.008","article-title":"Use of serum c-peptide level to simplify diabetes treatment regimens in older adults","volume":"122","author":"Munshi","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2025.113056_b0290","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-1966. doi: 10.1007\/s00125-022-05787-2. Epub 2022 Sep 24.","DOI":"10.1007\/s00125-022-05787-2"},{"key":"10.1016\/j.diabres.2025.113056_b0295","doi-asserted-by":"crossref","unstructured":"Munshi M,Kahkoska AR,Neumiller JJ,Alexopoulos AS,Allen NA5,Cukierman-Yaffe T, Huang ES,Lee SJ,Lipska KJ, McCarthy LM,Meneilly GS, Pandya N,Pratley RE,Rodriguez-Ma\u00f1as L,Sinclair AJ,Sy SL,Toschi E,Weinstock RS. Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies. Lancet Diabetes Endocrinol.2025 May;13(5):427-437.doi: 10.1016\/S2213-8587(24)00372-3.Epub 2025 Feb 17.","DOI":"10.1016\/S2213-8587(24)00372-3"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272501071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272501071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:22:25Z","timestamp":1769696545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272501071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":59,"alternative-id":["S016882272501071X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113056","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deinsulinisation in type 2 Diabetes: Evidence-based strategies for safe treatment simplification \u201cApproaches to reducing insulin in type 2 diabetes\u201d","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113056"}}